Abstract
Since 1948, when Farber et al. introduced aminopterin, the first chemotherapeutic agent, more than 100 such agents have come into use. Initially, antitumor chemotherapies were thought to produce only antiproliferative or cytotoxic effects on dividing tumor cells as it was often associated with the damage to healthy tissues and the development of resistant tumor clones. However, that view has been changing as a consequence of recent demonstrations that several antineoplastic drugs, even at low doses, have antiangiogenic and sometimes immunomodulating effects. In addition, new studies indicate that lowering the dose of conventional cytotoxic agents and combining chemotherapy with other modalities may not only decrease the toxicity of conventional chemotherapy, but also up-regulate the efficacy of different anticancer therapies. Giving chemotherapy in this manner has several potential advantages, including impediment of the onset of mutation-dependent mechanisms of acquired drug resistance and increase in the efficacy and durability of combinatorial therapeutic modalities. Certain “immunogenic” forms of cancer chemotherapy may cause indirect activation of immune cells due to the accessibility of tumor antigens and certain “danger” signals. Furthermore, new findings indicate that several chemotherapeutic agents can directly activate immune cells when used in ultra low noncytotoxic concentrations, the new phenomenon that was termed chemoimmunomodulation. The goal of this review is to analyze the immune modulating properties of antineoplastic chemotherapeutic agents and present new evidence of the immunostimulating potentials of several agents used in low and ultra low nontoxic doses. Therapeutic potentials of combined chemo-immunotherapeutic regimens have been extensively reviewed in a variety of recent publications and will not be discussed.
Keywords: Chemotherapy, chemomodulation, chemoimmunomodulation, immunostimulation, immunosuppression, paclitaxel
Current Medicinal Chemistry
Title:ChemoImmunoModulation: Immune Regulation by the Antineoplastic Chemotherapeutic Agents
Volume: 19 Issue: 12
Author(s): M. R. Shurin, H. Naiditch, D. W. Gutkin, V. Umansky and G. V. Shurin
Affiliation:
Keywords: Chemotherapy, chemomodulation, chemoimmunomodulation, immunostimulation, immunosuppression, paclitaxel
Abstract: Since 1948, when Farber et al. introduced aminopterin, the first chemotherapeutic agent, more than 100 such agents have come into use. Initially, antitumor chemotherapies were thought to produce only antiproliferative or cytotoxic effects on dividing tumor cells as it was often associated with the damage to healthy tissues and the development of resistant tumor clones. However, that view has been changing as a consequence of recent demonstrations that several antineoplastic drugs, even at low doses, have antiangiogenic and sometimes immunomodulating effects. In addition, new studies indicate that lowering the dose of conventional cytotoxic agents and combining chemotherapy with other modalities may not only decrease the toxicity of conventional chemotherapy, but also up-regulate the efficacy of different anticancer therapies. Giving chemotherapy in this manner has several potential advantages, including impediment of the onset of mutation-dependent mechanisms of acquired drug resistance and increase in the efficacy and durability of combinatorial therapeutic modalities. Certain “immunogenic” forms of cancer chemotherapy may cause indirect activation of immune cells due to the accessibility of tumor antigens and certain “danger” signals. Furthermore, new findings indicate that several chemotherapeutic agents can directly activate immune cells when used in ultra low noncytotoxic concentrations, the new phenomenon that was termed chemoimmunomodulation. The goal of this review is to analyze the immune modulating properties of antineoplastic chemotherapeutic agents and present new evidence of the immunostimulating potentials of several agents used in low and ultra low nontoxic doses. Therapeutic potentials of combined chemo-immunotherapeutic regimens have been extensively reviewed in a variety of recent publications and will not be discussed.
Export Options
About this article
Cite this article as:
R. Shurin M., Naiditch H., W. Gutkin D., Umansky V. and V. Shurin G., ChemoImmunoModulation: Immune Regulation by the Antineoplastic Chemotherapeutic Agents, Current Medicinal Chemistry 2012; 19 (12) . https://dx.doi.org/10.2174/092986712800099785
DOI https://dx.doi.org/10.2174/092986712800099785 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hardware and Software Approaches to Multi-Modality Imaging
Current Medical Imaging HIF1A is Overexpressed in Medulloblastoma and its Inhibition Reduces Proliferation and Increases EPAS1 and ATG16L1 Methylation
Current Cancer Drug Targets Recent Advances in Nanoneurology for Drug Delivery to the Brain
Current Nanoscience Nonalcoholic Fatty Liver Disease In Children: Recent Practice Guidelines, Where Do They Take Us?
Current Pediatric Reviews Differentiation Potential of Human Retinoblastoma Cells
Current Pharmaceutical Biotechnology An Overview of Acute Flaccid Myelitis
CNS & Neurological Disorders - Drug Targets Wzy-Dependent Bacterial Capsules as Potential Drug Targets
Current Drug Targets The Human Microbiome Project, Personalized Medicine and the Birth of Pharmacomicrobiomics
Current Pharmacogenomics and Personalized Medicine Nanotechnology, A Tool for Diagnostics and Treatment of Cancer
Current Topics in Medicinal Chemistry Keratin 18, Apoptosis, and Liver Disease in Children
Current Pediatric Reviews Smart Phones As a Viable Data Collection Tool in Low-resource Settings: Case Study of Rwandan Community Health Workers
Neuroscience and Biomedical Engineering (Discontinued) Recent Advances in Immunotherapy for Allergic Diseases
Recent Patents on Inflammation & Allergy Drug Discovery Therapeutic Use of Vitamin D and its Analogues in Autoimmunity
Recent Patents on Inflammation & Allergy Drug Discovery Foods for Health and to Treat Diseases
Current Pediatric Reviews Epigenetics and the Environmental Regulation of the Brain's Genome and its Function
Current Psychiatry Reviews Pharmaceutical Interventions for Frailty and Sarcopenia
Current Pharmaceutical Design Meet Our Section Editor
Current Diabetes Reviews Drug-Induced Thromboembolic Events in Patients with Malignancy
Cardiovascular & Hematological Disorders-Drug Targets Search for Distinctive Markers in DNT and Cortical Grade II Glioma in Children: Same Clinicopathological and Molecular Entities?
Current Topics in Medicinal Chemistry Polycystic Ovary Syndrome in Adolescents
Current Women`s Health Reviews